Ultrasound-activated nanocarrier targeting macrophages for myocardial infarction
Author Information
Author(s): Ma Zhen, Li Ming, Guo Rui, Tian Yu, Zheng Yongbin, Huang Bingxin, You Yi, Xu Qing, Cui Ming, Shen Li, Lan Feng, Yang Hang, Liu Rucong, Yang Tao, Wan Feng, He Qihua, Huo Xiao, Bi Youkun, Zhang Yingying, Ling Yunpeng
Primary Institution: Peking University Third Hospital
Hypothesis
Can a nanotherapeutic delivery system specifically target CD86-positive macrophages and improve outcomes after myocardial infarction?
Conclusion
The study developed a targeted drug delivery system that effectively delivers therapeutics to macrophages in the heart, improving cardiac function after myocardial infarction.
Supporting Evidence
- FA-PNBs effectively target CD86-positive macrophages in the infarct area.
- Ultrasound activation enhances the release of therapeutics from FA-PNBs.
- Combined treatment with OA-NO2 and siSTAT1 improves cardiac function post-MI.
- Significant reduction in pro-inflammatory cytokines was observed.
- Increase in Cx3cr1-positive macrophages was noted after treatment.
- Treatment led to improved echocardiographic measures of cardiac function.
- Histological analysis showed reduced fibrosis in treated mice.
Takeaway
Researchers created a special delivery system that helps medicine reach the right cells in the heart after a heart attack, which can help the heart heal better.
Methodology
The study engineered a folic acid-modified ultrasound-responsive gene/drug delivery system to target CD86-positive macrophages and deliver siRNA and nitro-oleic acid.
Limitations
The study did not explore the long-term effects of the treatment or the exact mechanisms of macrophage transformation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website